SLXN
Silexion Therapeutics Ltd. NASDAQ Listed Aug 16, 2024$0.39
After hrs
$0.38
-3.07%
Mkt Cap $524.0K
52w Low $0.27
1.7% of range
52w High $7.74
50d MA $2.11
200d MA $2.03
P/E (TTM)
0.0x
EV/EBITDA
—
P/B
0.2x
Debt/Equity
0.2x
ROE
-457.6%
P/FCF
-0.0x
RSI (14)
5.10
ATR (14)
$0.15
Beta
0.06
50d MA
$2.11
200d MA
$2.03
Avg Volume
419.2K
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
The Goldyne Savad Institute of Gene Therapy · Jerusalem, L3 9112001 · IL
Data updated apr 27, 2026 1:49am
· Source: financialmodelingprep.com